ABSTRACT
Cardiac involvement in systemic sclerosis (SSc) is rare but leads to poor short-term prognosis. Evidence regarding heart transplantation (HT) is scarce and is based on experience with isolated cases. We present this case with the aim of analysing the characteristics of a patient with SS who has undergone a successful transplant.
Subject(s)
Heart Transplantation , Scleroderma, Systemic , Humans , Scleroderma, Systemic/complications , Scleroderma, Systemic/surgeryABSTRACT
Cardiac involvement in systemic sclerosis (SSc) is rare but leads to poor short-term prognosis. Evidence regarding heart transplantation (HT) is scarce and is based on experience with isolated cases. We present this case with the aim of analysing the characteristics of a patient with SS who has undergone a successful transplant.(AU)
El compromiso cardíaco en la esclerosis sistémica (ES) es raro, pero conlleva un mal pronóstico a corto plazo. La evidencia relativa al trasplante cardíaco (TC) es escasa y se basa en la experiencia con los casos aislados. Presentamos este caso con el objetivo de analizar las características de un paciente con esclerosis sistémica sometido a un trasplante exitoso.(AU)
Subject(s)
Humans , Male , Middle Aged , Scleroderma, Systemic , Heart Transplantation , Myositis , Patient Care , RheumatologyABSTRACT
Cardiac involvement in systemic sclerosis (SSc) is rare but leads to poor short-term prognosis. Evidence regarding heart transplantation (HT) is scarce and is based on experience with isolated cases. We present this case with the aim of analysing the characteristics of a patient with SS who has undergone a successful transplant.
ABSTRACT
OBJETIVOS: Describir pacientes con aortitis no infecciosa y su respuesta al tratamiento de un hospital comarcal. MÉTODOS: Revisión de pacientes con aortitis no infecciosa, técnica diagnóstica utilizada y tratamiento inmunosupresor recibido. RESULTADOS: Se encontraron 8 pacientes (7 mujeres y un hombre) diagnosticados de aortitis mediante tomografía por emisión de positrones (PET). La mediana de edad fue de 69 años (IQR62-72,2). Tocilizumab (TCZ) mejoró los síntomas, la VSG y la PCR a los 3meses del tratamiento (p < 0,001 y p < 0,012, respectivamente) en los 6 pacientes en que se utilizó. CONCLUSIÓN: TCZ fue eficaz y seguro en los pacientes que fueron refractarios a esteroides y a otros tratamientos inmunosupresores
OBJECTIVES: Describe patients with noninfectious aortitis and their response to treatment in a regional hospital. METHODS: Review of patients with noninfectious aortitis, diagnostic technique used and immunosuppressive therapy received. RESULTS: We report 8 patients (7 women and one man) diagnosed with aortitis by positron emission tomography (PET). The mean age was 69 years (interquartile range [IQR] 62-72.2). Three months of treatment with tocilizumab improved symptoms, erythrocyte sedimentation rate and C-reactive protein level (P<.001 and P<.012, respectively) in the 6 patients in whom it was used. CONCLUSIONS: Tocilizumab was an effective and safe treatment in those patients diagnosed with aortitis refractory to steroids and conventional immunosuppressive therapy
Subject(s)
Humans , Male , Female , Middle Aged , Aged , Antibodies, Monoclonal, Humanized/therapeutic use , Aortitis/drug therapy , Aortitis/diagnosis , Hospitals , Retrospective Studies , SpainABSTRACT
OBJECTIVES: Describe patients with noninfectious aortitis and their response to treatment in a regional hospital. METHODS: Review of patients with noninfectious aortitis, diagnostic technique used and immunosuppressive therapy received. RESULTS: We report 8 patients (7 women and one man) diagnosed with aortitis by positron emission tomography (PET). The mean age was 69years (interquartile range [IQR] 62-72.2). Three months of treatment with tocilizumab improved symptoms, erythrocyte sedimentation rate and C-reactive protein level (P<.001 and P<.012, respectively) in the 6 patients in whom it was used. CONCLUSIONS: Tocilizumab was an effective and safe treatment in those patients diagnosed with aortitis refractory to steroids and conventional immunosuppressive therapy.
